scholarly journals Effects of inflammatory bowel disease on in-hospital outcomes in patients with congestive heart failure: A retrospective national inpatient sample study

2019 ◽  
Vol 23 ◽  
pp. 100355
Author(s):  
Dhrubajyoti Bandyopadhyay ◽  
Vardhmaan Jain ◽  
Adrija Hajra ◽  
Sandipan Chakraborty ◽  
Raktim K. Ghosh ◽  
...  
Keyword(s):  
Heart Failure ◽  
Inflammatory Bowel Disease ◽  
Congestive Heart Failure ◽  
Bowel Disease ◽  
National Inpatient Sample ◽  
Hospital Outcomes ◽  
Inflammatory Bowel

Coexisting psoriasis is associated with an increased risk of hospitalization for patients with inflammatory bowel disease: an analysis of the National Inpatient Sample database

2020 ◽  
pp. jim-2020-001689
Author(s):  
Ehizogie Edigin ◽  
Jennifer Asotibe ◽  
Precious Obehi Eseaton ◽  
Olukayode Ahmed Busari ◽  
Ikechukwu Achebe ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Kidney Injury ◽  
Hospital Charges ◽  
Multivariate Logistic Regression Model ◽  
Secondary Diagnosis ◽  
National Inpatient Sample ◽  
Hospital Outcomes ◽  
Increased Risk ◽  
Inflammatory Bowel

This study compares the odds of being admitted for inflammatory bowel disease (IBD) in patients with psoriasis compared with those without psoriasis alone. We also compared hospital outcomes of patients admitted primarily for IBD with and without a secondary diagnosis of psoriasis. Data were abstracted from the National Inpatient Sample (NIS) 2016 and 2017 database to search for hospitalizations of interest using International Classification of Diseases, 10th Revision codes. Multivariate logistic regression model was used to calculate the adjusted OR (AOR) of IBD being the principal diagnosis for hospitalizations with and without a secondary diagnosis of psoriasis. Multivariate logistic and linear regression analyses were used accordingly to compare outcomes of hospitalizations for IBD with and without secondary diagnosis of psoriasis. There were over 71 million discharges included in the combined 2016 and 2017 NIS database. Hospitalizations with a secondary diagnosis of psoriasis have an AOR of 2.66 (95% CI 2.40 to 2.96, p<0.0001) of IBD being the principal reason for hospitalization compared with hospitalizations without psoriasis as a secondary diagnosis. IBD hospitalizations with coexisting psoriasis have similar lengths of stay, hospital charges, need for blood transfusion, and similar likelihood of having a secondary discharge diagnosis of deep venous thrombosis, gastrointestinal bleed, sepsis, and acute kidney injury compared with those without coexisting psoriasis. Patients with coexisting psoriasis have almost three times the odds of being admitted for IBD compared with patients without psoriasis. Hospitalizations for IBD with coexisting psoriasis have similar hospital outcomes compared with those without coexisting psoriasis.

scholarly journals In-hospital outcomes of inflammatory bowel disease in cannabis users: a nationwide propensity-matched analysis in the United States

2019 ◽  
Vol 7 (12) ◽  
pp. 252-252 ◽  
Author(s):  
Rupak Desai ◽  
Upenkumar Patel ◽  
Hemant Goyal ◽  
Afrina Hossain Rimu ◽  
Dipen Zalavadia ◽  
...  
Keyword(s):  
United States ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
The United States ◽  
Hospital Outcomes ◽  
Inflammatory Bowel

Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease

2020 ◽  
Author(s):  
Preetika Sinh ◽  
Raymond Cross
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Inflammatory Bowel Disease ◽  
Cardiovascular Risk ◽  
Lupus Erythematosus ◽  
Bowel Disease ◽  
Severe Heart Failure ◽  
Janus Kinase ◽  
Increased Risk ◽  
Inflammatory Bowel

Abstract There is increased risk of cardiovascular disease in patients with chronic inflammatory disorders such as rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Studies have shown association between cardiovascular disease (eg, myocardial infarction, heart failure, stroke) and inflammatory bowel disease. Medications such as infliximab and adalimumab (monoclonal antibodies to tumor necrosis factor α) may help decrease the inflammatory burden and cardiovascular risk; however, there have been reports of hypertriglyceridemia and worsening of moderate to severe heart failure with these medications. Janus kinase inhibitors, such as tofacitinib, have been associated with hyperlipidemia and thromboembolism. We aim to discuss clinical and imaging modalities to assess cardiovascular risk in inflammatory bowel disease patients and review the role of various medications with respect to cardiovascular disease in this population.

P-025 YI Hospital Outcomes of Early Sigmoidoscopy or Colonoscopy in Patients Admitted With Exacerbation of Inflammatory Bowel Disease

2014 ◽  
Vol 20 ◽  
pp. S32
Author(s):  
Obi Kenneth ◽  
Arsenescu Razvan ◽  
Conwell Darwin ◽  
Levine Edward ◽  
Hinton Alice ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Hospital Outcomes ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document